The impact of b/tsdmard dose reduction on chronic hepatitis b in rheumatoid arthritis patients: a two-center long-term safety analysis

HIGHLIGHTS

• who: Der-Yuan Chen and collaborators from the Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan have published the research: The Impact of b/tsDMARD Dose Reduction on Chronic Hepatitis B in Rheumatoid Arthritis Patients: A Two-Center Long-Term Safety Analysis, in the Journal: (JOURNAL) of 15/Nov/2022
• what: The authors aimed to investigate the change of B virus (HBV) viral loads and HBV reactivation (HBVr) in rheumatoid arthritis (RA) patients after tapering the of biological/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). In this retrospective observational study with a . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.